Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083959 | 0.90 | TRPV1 (0.63) | TRPV1PTGS1DEGS1RPS6KA3 | |
| SCHEMBL14083442 | 0.87 | TRPV1 (0.79) | TRPV1PTGS1DEGS1HIF1AEPAS1 | |
| SCHEMBL4464126 | 0.87 | TRPV1 (1.00) | TRPV1PTGS1DEGS1 | |
| SCHEMBL14083616 | 0.85 | TRPV1 (0.60) | TRPV1PTGS1RPS6KA3 | |
| SCHEMBL14083683 | 0.85 | TRPV1 (0.60) | TRPV1PTGS1DEGS1RPS6KA3HIF1A | |
| SCHEMBL4814175 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14083556 | 0.84 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL14083363 | 0.84 | TRPV1 (0.61) | TRPV1PTGS1RPS6KA3 | |
| SCHEMBL14083552 | 0.84 | TRPV1 (0.57) | TRPV1DEGS1 | |
| SCHEMBL14083136 | 0.84 | TRPV1 (0.73) | TRPV1PTGS1DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664041-B1 | PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-07-02 | — | — | EP | claimed |
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885PTGS1 215/4885DEGS1 1167/4885 |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885PTGS1 1926/4885DEGS1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.